To the Editor I am writing to report that I had failed to declare several conflicts of interest relevant to the subject of my Invited Commentary1 on 2 studies on gene expression profiles for uveal melanoma.2,3 In January 2016, I participated in a uveal melanoma meeting hosted by Castle Biosciences as a member of the Castle Biosciences Advisory Board, for which I received compensation. I also have received compensation for my role as an advisory board member of Aura Biosciences and Iconic Therapeutics related to investigations of novel therapies for primary uveal melanoma. I also have a pending patent application for a risk calculator of vision loss following brachytherapy.